BOWIE, Md., Feb. 3, 2011 /PRNewswire/ -- MedAssurant, Inc., a leading provider of data-driven healthcare solutions, today announced the initiation of a joint study with the University of North Carolina (UNC) to assess the relationship between the use of long-acting insulin to treat diabetes and the development of cancer. Following a protocol to be developed by UNC, MedAssurant has been engaged to analyze data from its MORE2 Registry™ comparing cancer prevalence and outcomes in patients treated with two different types of prescription insulin.
Recent publications have suggested a relationship may exist between a specific type of prescription long-acting insulin and increased rates of cancer development. Due to the inconsistent findings within these previous publications, this study is designed to further clarify the possible correlation using several very large and statistically powerful clinical and administrative healthcare databases, including MedAssurant's MORE2 Registry. As one of the most significant healthcare datasets available for such analysis, the MORE2 Registry contains more than 3.9 billion medical events from more than 76 million patients, 295,000 physicians, and 185,000 clinical facilities – enabling significant power and insight into the investigation of advancements in healthcare.
MedAssurant will be responsible for coordinating the identification of specific cohorts within the MORE2 Registry, the evaluation of clinical covariates that may affect incidences of cancer, and the application of advanced clinical analytics to assess the relationship between prescription insulin and cancer development.
"Depth of data is critical to this study and is believed to have been a significant limitation in past studies," stated John Buse, M.D., Ph.D., Chief of Endocrinology and Professor of Medicine, UNC. "We are delighted to have access to the analytical capabilities and data insight able to be brought to bear by MedAssurant and look forward to the additional power that this will bring to our research on the topic."
"Postmarketing surveillance is an important tool in determining the long-term safety of approved drugs," says Stephen DeCherney, M.D., M.P.H., a senior vice president of pharmaceuticals & life sciences at MedAssurant. "In this case, the growing number of people suffering from diabetes makes a meaningful evaluation of various long-acting prescription insulin medications an important undertaking. Unfortunately, previous studies have been challenged by smaller sample sizes, limited patient information, and short observation periods. In our work with UNC, we have the benefit of the MORE2 Registry, a rich database both in volume and in duration of information that will allow us to understand more deeply the long-term safety risks associated with long-acting prescription insulin."
About MedAssurant, Inc. MedAssurant, Inc., is a leading technology-enabled healthcare solutions provider focused on the importance of healthcare data and its ability to drive dramatic, objective improvement in clinical and quality outcomes, care management and financial performance throughout the healthcare community. Proprietary healthcare datasets, aggregation and analysis capabilities, combined with a national infrastructure of leading-edge technology, clinical prowess and deep human resources, empowers MedAssurant's advanced generation of healthcare assessment and improvement through highly informed solutions. Driven by a mission to improve today's healthcare landscape, the employees of MedAssurant proudly apply care, ingenuity and dedication to delivering a new approach to healthcare touching more than 100 million Americans – one driven by data and insight – one resulting in meaningful action. Please visit www.medassurant.com for more information.Contacts: Russo Partners LLC on behalf of MedAssurant, Inc. Tony Russo or Lena EvansPhone: 212-845-4251Phone: email@example.com@russopartnersllc.comMedAssurant, Inc.Alex Burgess4321 Collington RoadBowie, Maryland 20716Phone: firstname.lastname@example.org
|SOURCE MedAssurant, Inc.|
Copyright©2010 PR Newswire.
All rights reserved